Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel
Medison Pharma Ltd a global pharma company focused on providing access to highly innovative therapies to patients in international markets, announced today the expansion of its partnership with Albireo to a multi-regional agreement to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Albireo's vote of confidence in the commercial solution Medison offers allows us to continue demonstrating our ongoing commitment to accelerate access to highly innovative therapies in international markets", said Meir Jakobsohn, Founder and CEO of Medison and added "Expanding our partnership with Albireo to the Canadian market enables us to offer innovative solutions to patients suffering from rare cholestatic liver diseases and improve their lives also in this important market".
"We are privileged to expand the access of Albireo's innovative treatment to additional markets and compliment Albireo's global commercial strategy", said Gil Gurfinkel, VP Corporate Development at Medison. "Our multi-regional platform makes us the partner-of-choice for emerging biotech companies seeking to make their innovative products available in international markets for the benefit of patients suffering from severe conditions".
Odevixibat is approved in Europe as Bylvay
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!